See more : IVE Group Limited (IGL.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Genetron Holdings Limited (GTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genetron Holdings Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Energold Drilling Corp. (EGDFF) Income Statement Analysis – Financial Results
- Focus Dynamics Group Berhad (0116.KL) Income Statement Analysis – Financial Results
- Induction Healthcare Group PLC (INHC.L) Income Statement Analysis – Financial Results
- Bausen Inc. (2948.TWO) Income Statement Analysis – Financial Results
- Vani Commercials Limited (VANICOM.BO) Income Statement Analysis – Financial Results
Genetron Holdings Limited (GTH)
About Genetron Holdings Limited
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 650.71M | 531.95M | 424.49M | 323.43M | 225.18M | 101.03M |
| Cost of Revenue | 369.28M | 193.98M | 164.27M | 178.44M | 132.45M | 74.21M |
| Gross Profit | 281.43M | 337.97M | 260.22M | 144.99M | 92.73M | 26.82M |
| Gross Profit Ratio | 43.25% | 63.53% | 61.30% | 44.83% | 41.18% | 26.55% |
| Research & Development | 290.29M | 253.95M | 149.00M | 91.70M | 71.41M | 45.78M |
| General & Administrative | 266.91M | 227.00M | 126.32M | 117.17M | 88.23M | 45.49M |
| Selling & Marketing | 364.56M | 343.16M | 246.96M | 253.56M | 182.47M | 94.57M |
| SG&A | 631.47M | 570.16M | 373.28M | 370.73M | 270.71M | 140.06M |
| Other Expenses | -8.71M | -5.33M | -8.53M | -10.85M | -233.63M | -258.11M |
| Operating Expenses | 913.05M | 818.78M | 513.75M | 451.58M | 332.19M | 181.01M |
| Cost & Expenses | 1.28B | 1.01B | 678.02M | 630.01M | 464.64M | 255.22M |
| Interest Income | 2.86M | 20.50M | 28.33M | 441.00K | 1.55M | 513.00K |
| Interest Expense | 111.49M | 5.25M | 5.63M | 5.40M | 0.00 | 669.00K |
| Depreciation & Amortization | 85.39M | 20.50M | -2.80B | -319.22M | 27.86M | 20.61M |
| EBITDA | -651.24M | -460.32M | -201.69M | -625.81M | -212.21M | -134.08M |
| EBITDA Ratio | -83.94% | -86.53% | -718.18% | -193.49% | -197.04% | -397.06% |
| Operating Income | -631.62M | -480.82M | -253.53M | -306.59M | -232.98M | -152.54M |
| Operating Income Ratio | -97.07% | -90.39% | -59.73% | -94.79% | -103.46% | -150.98% |
| Total Other Income/Expenses | -108.69M | 21.04M | -2.80B | -366.94M | -225.53M | -268.10M |
| Income Before Tax | -810.63M | -502.60M | -3.07B | -676.03M | -464.99M | -420.64M |
| Income Before Tax Ratio | -124.58% | -94.48% | -723.00% | -209.02% | -206.50% | -416.34% |
| Income Tax Expense | 73.26M | -64.19M | -2.87B | -354.54M | -232.02M | -257.44M |
| Net Income | -883.89M | -438.40M | -198.11M | -321.49M | -464.99M | -420.64M |
| Net Income Ratio | -135.84% | -82.41% | -46.67% | -99.40% | -206.50% | -416.34% |
| EPS | -9.53 | -4.76 | -3.29 | -4.65 | -6.73 | -6.22 |
| EPS Diluted | -9.53 | -4.76 | -3.29 | -4.65 | -6.73 | -6.22 |
| Weighted Avg Shares Out | 92.80M | 92.11M | 60.28M | 69.07M | 69.07M | 67.68M |
| Weighted Avg Shares Out (Dil) | 92.80M | 92.11M | 60.28M | 69.07M | 69.07M | 67.68M |
Gathid Sets New Identity and Access Governance Standard with Introduction of Patented Identity Model
Genetron Health Announces Completion of Going Private
Genetron Health Announces Completion of Going Private Transaction
Genetron Health Announces Shareholders' Approval of Merger Agreement
Genetron Health to Hold Extraordinary General Meeting of Shareholders
Genetron stock rallies on CEO-led deal to go private
Genetron Health Enters into Definitive Merger Agreement for Going Private Transaction
Genetron Health Announces Receipt of Notification from
Genetron Health Announces Receipt of a Preliminary
Genetron Holdings Limited (GTH) CEO Sizhen Wang on Q1 2022 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports